FDA
-
-
-
-
-
-
-
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
-
-
-
-
-
-
-
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines’ Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Canc
-
-
-
-
-
-
-
Tango Therapeutics, Inc (TNGX) Reports Positive TNG462 Clinical Data, Provides Update on PRMT5 Development Program
-
-
-
-
-
-
-
Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer
-
-
-
-
-
-
-
Tango Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights
-
-
-
-
-
-
-
Tango Therapeutics Announces Clearance of TNG908 IND by FDA and Recent Pipeline Progress Updates
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

